Dotmatics, a global leader in scientific software for R&D, has announced its latest acquisition of Virscidian, a provider of specialized analytical chemistry solutions. This marks Dotmatics’ 15th acquisition as the company strengthens its portfolio of automated laboratory workflows, particularly in chromatography and mass spectrometry data processing. The acquisition further enhances Dotmatics’ capabilities in providing integrated scientific tools for better data-driven decision-making across various research and development sectors.
Virscidian’s flagship product, Analytical Studio, is a powerful platform designed to automate complex laboratory workflows, allowing scientists to process vast amounts of data quickly and efficiently. According to Dotmatics, this addition is set to enhance their existing capabilities by integrating with their Luma Scientific Intelligence Platform, which uses AI and machine learning to streamline research workflows.
Enhancing Analytical Capabilities
Virscidian’s Analytical Studio offers modules that automate chromatography and mass spectrometry workflows, which are crucial in small molecule research. By incorporating high-quality, AI/ML-ready data, Virscidian enhances experimental designs, purification processes, and sample quality control. This, in turn, provides researchers with more accurate results and faster data analysis, making the drug discovery process more efficient.
Thomas Swalla, CEO of Dotmatics, highlighted the synergy between the two companies: “Virscidian’s expertise in chromatography and mass spectrometry workflows complements the solutions we offer through Protein Metrics for large molecule R&D. By integrating their technology with our Luma platform, we can offer an end-to-end solution that supports our customers’ need for automation and increased accuracy in scientific research.”
Virscidian’s Analytical Studio consists of key modules such as AS-Professional, AS-Experiment Builder, AS-Fraction Mapper, and AS-Sample Management Services, which allow for seamless integration with internal and third-party informatics environments. This flexibility enables scientists to optimize experimental designs, manage large datasets, and automate intricate workflows efficiently.
Leveraging AI and ML for Scientific Advancements
Dotmatics has been investing heavily in AI and machine learning to transform scientific research, and the acquisition of Virscidian further enhances their efforts. Dotmatics’ Luma platform is designed to unify, analyze, and visualize large volumes of scientific data, improving decision-making through AI-enabled workflows. The platform supports a range of research areas, including genomics, proteomics, and metabolomics, allowing scientists to handle complex datasets with ease.
The integration of Virscidian’s technology into Luma will expand Dotmatics’ capabilities in analytical chemistry, particularly in small molecule research. By leveraging AI and ML, Dotmatics aims to improve the speed and accuracy of scientific discoveries, making processes like drug discovery more streamlined and data-driven.
Joseph Simpkins, Founder and President of Virscidian, expressed his excitement about joining forces with Dotmatics. “We’ve built a powerful, flexible platform for laboratory informatics, and by combining it with Dotmatics’ existing tools, we can offer a more comprehensive solution to our customers. Together, we will enable scientists to unlock new possibilities in drug discovery and beyond.”
Strategic Growth and Future Innovation
This acquisition aligns with Dotmatics’ long-term strategy of building a comprehensive portfolio of scientific applications designed by scientists for scientists. Since 2017, Dotmatics has made 15 acquisitions, expanding its ability to integrate scientific data across multiple modalities. The company’s tools are used in a variety of sectors, including pharmaceuticals, biotechnology, and agriculture, where data management and automation are critical to driving innovation.
With Virscidian’s expertise now part of Dotmatics, the company is well-positioned to support more advanced analytical processes in laboratories around the world. Dotmatics’ vision is to continue empowering researchers with the tools they need to make faster, more informed decisions, ultimately accelerating scientific breakthroughs in areas like drug discovery, precision medicine, and synthetic biology.
